- Home
- TXMD vs CING Comparison
TXMD vs CING Comparison
Compare TXMD & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- CING
- Stock Information
- Founded
- TXMD 2008
- CING 2012
- Country
- TXMD United States
- CING United States
- Employees
- TXMD N/A
- CING N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- TXMD Health Care
- CING Health Care
- Exchange
- TXMD Nasdaq
- CING Nasdaq
- Market Cap
- TXMD 12.8M
- CING 15.3M
- IPO Year
- TXMD N/A
- CING 2021
- Fundamental
- Price
- TXMD $1.00
- CING $4.45
- Analyst Decision
- TXMD
- CING Strong Buy
- Analyst Count
- TXMD 0
- CING 3
- Target Price
- TXMD N/A
- CING $16.00
- AVG Volume (30 Days)
- TXMD 113.1K
- CING 222.0K
- Earning Date
- TXMD 03-28-2025
- CING 11-07-2024
- Dividend Yield
- TXMD N/A
- CING N/A
- EPS Growth
- TXMD N/A
- CING N/A
- EPS
- TXMD N/A
- CING N/A
- Revenue
- TXMD $1,596,000.00
- CING N/A
- Revenue This Year
- TXMD $605.07
- CING N/A
- Revenue Next Year
- TXMD $1.11
- CING N/A
- P/E Ratio
- TXMD N/A
- CING N/A
- Revenue Growth
- TXMD N/A
- CING N/A
- 52 Week Low
- TXMD $0.70
- CING $1.80
- 52 Week High
- TXMD $2.75
- CING $20.83
- Technical
- Relative Strength Index (RSI)
- TXMD 41.47
- CING 43.28
- Support Level
- TXMD $0.99
- CING $4.35
- Resistance Level
- TXMD $1.13
- CING $4.69
- Average True Range (ATR)
- TXMD 0.06
- CING 0.37
- MACD
- TXMD -0.00
- CING -0.07
- Stochastic Oscillator
- TXMD 5.26
- CING 12.33
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.